Analysts Offer Predictions for AngioDynamics FY2025 Earnings

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Analysts at Zacks Research lifted their FY2025 earnings per share (EPS) estimates for AngioDynamics in a research note issued to investors on Wednesday, April 23rd. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn ($0.32) per share for the year, up from their prior forecast of ($0.38). The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics' Q4 2025 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at $0.03 EPS, FY2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.10) EPS and Q2 2027 earnings at ($0.06) EPS.

Separately, HC Wainwright restated a "buy" rating and set a $16.00 price target (up previously from $15.00) on shares of AngioDynamics in a research note on Monday, April 7th.

AngioDynamics Stock Down 0.4 %

Shares of NASDAQ ANGO traded down $0.04 during midday trading on Friday, reaching $9.60. 213,760 shares of the company's stock traded hands, compared to its average volume of 560,617. The stock's 50 day simple moving average is $9.56 and its 200-day simple moving average is $9.15. The company has a market cap of $389.83 million, a price-to-earnings ratio of -1.71 and a beta of 0.52. AngioDynamics has a one year low of $5.47 and a one year high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. The firm had revenue of $72.00 million during the quarter, compared to the consensus estimate of $70.30 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The firm's quarterly revenue was down 4.3% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. purchased a new stake in AngioDynamics in the 4th quarter valued at $28,000. R Squared Ltd acquired a new position in AngioDynamics during the fourth quarter worth $49,000. US Bancorp DE boosted its position in shares of AngioDynamics by 1,938.0% in the 4th quarter. US Bancorp DE now owns 6,705 shares of the medical instruments supplier's stock worth $61,000 after buying an additional 6,376 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new stake in shares of AngioDynamics in the fourth quarter valued at approximately $92,000. Finally, ProShare Advisors LLC acquired a new position in shares of AngioDynamics in the fourth quarter worth $100,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.